Which Peptides Are Discussed in Perimenopause, and How Do They Fit With HRT?

PT-141 (bremelanotide) is the only peptide with FDA approval for low sexual desire, and that approval covers premenopausal women only, so use in perimenopause is off-label. Clinicians discuss it as an on-demand choice to add when desire stays low even after estrogen and progesterone feel steady. Peptides mentioned for energy or sleep have no trials showing those benefits in perimenopause.

Is any peptide approved for low desire in perimenopause?

Two 24-week trials tested bremelanotide as needed in premenopausal women who had low desire with distress. Women on bremelanotide reported higher desire and lower distress than women on placebo RECONNECT trials. The FDA approved the injection for acquired, generalized low desire in premenopausal women FDA review. Women past menopause were not in those trials.

The brand version, Vyleesi, is taken about 45 minutes before sexual activity, with no daily dosing. Nausea, flushing and headache were among the most common side effects Vyleesi label. Use during perimenopause falls outside the label and calls for clinician judgment about whether low desire with distress fits this treatment.

How does PT-141 fit if you're already on HRT?

PT-141 (bremelanotide) works through brain signals tied to desire. It does not raise estrogen or progesterone. Write-ups describe it as a choice to consider alongside HRT when low desire continues after hormones feel steady Peptide Mind overview. HRT keeps its own role for cycle changes, sleep disruption, hot flashes and vaginal dryness. No published reports describe a standard way to combine PT-141 with other peptides for desire. If you want help deciding whether desire needs a separate approach, take the quiz to have an HOD clinician review your history and current treatment.

What about peptides talked about for energy, sleep, and skin?

CJC-1295 with ipamorelin comes up for energy, sleep and body shape because it prompts the pituitary to release more growth hormone. A study in healthy adults found higher growth hormone and IGF-1, a related growth signal, after CJC-1295 physician review of perimenopause peptides. Menopause clinicians note those hormone changes did not lead to trials showing less weight gain, clearer thinking or better sleep in perimenopausal women, and most body-shape data come from animals or people with growth hormone deficiency Midi Health on CJC-1295. A separate review found no trial in perimenopausal or postmenopausal women where CJC-1295 with ipamorelin improved weight, thinking or sleep Menopause Reviewed on peptides.

Skin claims center on a different peptide. A cream with GHK-Cu, a copper peptide, applied twice daily for 8 weeks left wrinkles looking smaller and shallower in women 40 to 65 physician review of perimenopause peptides. Researchers did not test injections for hormones, sleep or energy in that skin trial.